158 related articles for article (PubMed ID: 38103759)
1. METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer.
Zhou S; Sheng L; Zhang L; Zhang J; Wang L
Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130542. PubMed ID: 38103759
[TBL] [Abstract][Full Text] [Related]
2. METTL3-mediated m
Zhou Z; Cao Y; Yang Y; Wang S; Chen F
Epigenetics; 2023 Dec; 18(1):2217033. PubMed ID: 37243702
[TBL] [Abstract][Full Text] [Related]
3. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
[TBL] [Abstract][Full Text] [Related]
4. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.
Fu W; Liu L; Tong S
Thorac Cancer; 2024 Jun; 15(17):1357-1368. PubMed ID: 38709912
[TBL] [Abstract][Full Text] [Related]
5. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
6. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
Yi J; Peng F; Zhao J; Gong X
Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
[TBL] [Abstract][Full Text] [Related]
7. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
Zhao C; Ling X; Xia Y; Yan B; Guan Q
Cancer Cell Int; 2021 Aug; 21(1):441. PubMed ID: 34419065
[TBL] [Abstract][Full Text] [Related]
8. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer.
Li S; Jiang F; Chen F; Deng Y; Pan X
J Biochem Mol Toxicol; 2022 Jan; 36(1):e22922. PubMed ID: 34964205
[TBL] [Abstract][Full Text] [Related]
9. METTL3-mediated m6A modification of EPPK1 to promote the development of esophageal cancer through regulating the PI3K/AKT pathway.
Jia J; Yu L
Environ Toxicol; 2024 May; 39(5):2830-2841. PubMed ID: 38293837
[TBL] [Abstract][Full Text] [Related]
10. METTL3 Reduces Oxidative Stress-induced Apoptosis in Presbycusis by Regulating the N6-methyladenosine Level of SIRT1 mRNA.
Wang E; Li Y; Li H; Liu Y; Ming R; Wei J; Du P; Li X; Zong S; Xiao H
Neuroscience; 2023 Jun; 521():110-122. PubMed ID: 37087022
[TBL] [Abstract][Full Text] [Related]
11. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
[TBL] [Abstract][Full Text] [Related]
12. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
[TBL] [Abstract][Full Text] [Related]
13. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
[TBL] [Abstract][Full Text] [Related]
14. METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma.
Liu B; Cao J; Wu B; Hao K; Wang X; Chen X; Shen Z
Cell Commun Signal; 2023 May; 21(1):121. PubMed ID: 37231451
[TBL] [Abstract][Full Text] [Related]
15. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
Ouyang D; Hong T; Fu M; Li Y; Zeng L; Chen Q; He H; Wen Y; Cheng Y; Zhou M; Zou Q; Yi W
Breast Cancer Res; 2023 Feb; 25(1):19. PubMed ID: 36765397
[TBL] [Abstract][Full Text] [Related]
16. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner.
Pan X; Hong X; Li S; Meng P; Xiao F
Exp Mol Med; 2021 Jan; 53(1):91-102. PubMed ID: 33420414
[TBL] [Abstract][Full Text] [Related]
17. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Ma Z; Li Q; Liu P; Dong W; Zuo Y
Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
[TBL] [Abstract][Full Text] [Related]
18. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
[TBL] [Abstract][Full Text] [Related]
19. METTL3-mediated m6A modification of SIRT1 mRNA inhibits progression of endometriosis by cellular senescence enhancing.
Wang X; Wang J; Zhao X; Wu H; Li J; Cheng Y; Guo Q; Cao X; Liang T; Sun L; Zhang G
J Transl Med; 2023 Jun; 21(1):407. PubMed ID: 37353804
[TBL] [Abstract][Full Text] [Related]
20. METTL3 Promotes Osteosarcoma Metastasis via an m6A-dependent Epigenetic Activity of CBX4.
Huo XS; Lu D; Chen DG; Ye M; Wang XW; Shang FS
Front Biosci (Landmark Ed); 2024 Mar; 29(3):120. PubMed ID: 38538251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
